---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-099872"
form_type: "8-K"
ticker: "NVCT"
cik: "0001875558"
company_name: "Nuvectis Pharma, Inc."
filed_at: "2023-09-12T23:59:59+00:00"
generated_at: "2026-06-10T21:23:51.892214+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nuvectis Pharma initiates Phase 1a trial of NXP900 for advanced solid tumors

## Summary
- Phase 1a dose-escalation study evaluates safety, tolerability, and PK of NXP900 in advanced solid tumor patients.
- NXP900 is a novel SRC/YES1 kinase inhibitor with low nanomolar IC50 (YES1: 0.5nM, SRC: 2.4nM).
- Preclinical models showed robust single-agent anti-cancer activity across several solid tumor types.
- CEO Ron Bentsur highlights NXP900's unique mechanism and target specificity versus multi-kinase inhibitors.

## SEC filing metadata
- accession: 0001104659-23-099872
- form_type: 8-K
- ticker: NVCT
- cik: 0001875558
- company_name: Nuvectis Pharma, Inc.
- filed_at: 2023-09-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1875558/000110465923099872/0001104659-23-099872-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1875558/000110465923099872/tm2325910d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-099872
- JSON: https://secwatch.observer/filing/0001104659-23-099872.json
- Plain text: https://secwatch.observer/filing/0001104659-23-099872.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.